Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

Bang, Yung-Jue; Kang, Yoon-Koo; K Kang, Won; Boku, Narikazu; C Chung, Hyun; Chen, Jen-Shi; Doi, Toshihiko; Sun, Yan; Shen, Lin; Qin, Shukui; Ng, Wai-Tong; M Tursi, Jennifer; J Lechuga, Maria; Ray Lu, Dongrui; Ruiz-Garcia, Ana; Sobrero, Alberto

doi:10.1007/s10637-010-9438-y

Public

Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

Shared by NobleBlocks on Dec 1, 2011 • 12:00 AM UTC

Authors:

Yung-Jue Bang

Yoon-Koo Kang

Won K Kang

Abstract

PURPOSE: This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had received prior chemotherapy. EXPERIMENTAL DESIGN: Patients received sunitinib 50 mg/day on...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!